Scinus Group strategic investment — Scinus Group

Scinus Group has secured a €3 million strategic investment, led by Myosotis Investments with participation from existing shareholders like Demcon Innovation Fund. This funding marks a significant step towards organizational maturity and will accelerate the global rollout of their GMP-compliant Osilaris cell expansion platform. The company plans to leverage these funds for commercial expansion in key markets, aiming to address manufacturing challenges in the growing cell therapy sector.